SEARCH

SEARCH BY CITATION

References

  • 1
    Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2011 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2012:Figure 6.8.
  • 2
    Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940.
  • 3
    Lucey MR, Terrault N, Ojo L, Hay JE, Neuberger J, Blumberg E, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 2013; 19: 3-26.
  • 4
    Wiesner RH, Fung JJ. Present state of immunosuppressive therapy in liver transplant recipients. Liver Transpl 2011; 17(suppl 3): S1-S9.
  • 5
    Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2011 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2012:Figure 7.4.
  • 6
    Hirose R, Vincenti F. Immunosuppression: today, tomorrow, and withdrawal. Semin Liver Dis 2006; 26: 201-210.
  • 7
    Goralczyk AD, Hauke N, Bari N, Tsui TY, Lorf T, Obed A. Interleukin 2 receptor antagonists for liver transplant recipients: a systematic review and meta-analysis of controlled studies. Hepatology 2011; 54: 541-554.
  • 8
    Salis P, Caccamo C, Verzaro R, Gruttadauria S, Artero M. The role of basiliximab in the evolving renal transplantation immunosuppression protocol. Biologics 2008; 2: 175-188.
  • 9
    Eghtesad B, Forrest T, Fijikl M, Diago T, Hodgkinson P, Hashimoto K, et al. A pilot randomized controlled clinical trial of thymoglobulin (r-ATG) induction with extended delay of calcineurin inhibitor therapy in liver transplantation—interim analysis. Liver Transpl 2011; 17: S85.
  • 10
    O'Grady JG, Hardy P, Burroughs AK, Elbourne D; for UK and Ireland Liver Transplant Study. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. Am J Transplant 2007; 7: 137-141.
  • 11
    Schlitt HJ, Barkmann A, Boker KH, Schmidt HH, Emmanouilidis N, Rosenau J, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001; 357: 587-591.
  • 12
    Boudjema K, Camus C, Saliba F, Calmus Y, Salame E, Pageaux G, et al. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant 2011; 11: 965-976.
  • 13
    DuBay D, Smith RJ, Qiu KG, Levy GA, Lilly L, Therapondos G. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens. Liver Transpl 2008; 14: 651-659.
  • 14
    De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, Saliba F, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant 2012; 12: 3008-3020.
  • 15
    Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010; 51: 1237-1243.
  • 16
    Post DJ, Douglas DD, Mulligan DC. Immunosuppression in liver transplantation. Liver Transpl 2005; 11: 1307-1314.
  • 17
    Garcia-Valdecasas JC, Feng S, Lake JR, Vargas HE, Wekerle T, Meadows-Shropshire S, et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II study [abstract]. Liver Transpl 2011; 17(suppl 1): S79.
  • 18
    Grinyó J, Charpentier B, Pestana JM, Vanrenterghem Y, Vincenti F, Reyes-Acevedo R, et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 2010; 90: 1521-1527.
  • 19
    Tedesco-Silva H, Kho MM, Hartmann A, Vitko S, Russ G, et al. Sotrastaurin in calcineurin inhibitor-free regimen using everolimus in de novo kidney transplant recipients. Am J Transplant 2013; 13: 1757-1768.
  • 20
    Starzl TE, Lakkis FG. The unfinished legacy of liver transplantation: emphasis on immunology. Hepatology 2006; 43: S151-S163.
  • 21
    Pons JA, Revilla Nuin B, Ramirez P, Baroja Mazo A, Martinez Alarcon L, Robles R, et al. What do we know about the clinical impact of complete withdrawal of immunosuppression in liver transplantation? Transplant Proc 2012; 44: 1530-1532.
  • 22
    Feng S, Ekong UD, Lobritto SJ, Demetris AJ, Roberts JP, Rosenthal P, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 2012; 307: 283-293.
  • 23
    Shaked A, Feng S, Punch J, Reyes J, Levitsky J, Klintmalm G, et al. Initial outcomes of early post-liver transplant immunosuppression withdrawal in ITN030ST [abstract]. Am J Transplant 2012; 12: 197.